Endocrine Abstracts

Background: Giant prolactinomas are rare pituitary tumours larger than >40 mm in diameter, representing 2–3% of prolactin secreting tumours. Management is challenging especially in male patients, due to resistance to dopamine agonists (DA).Methods: Clinical, hormonal and imaging evaluation and follow-upAim: To describe a case of partially resistant giant prolactinoma in a young male patientCase repor...

Background: PA is a frequent cause (5–13%) of secondary hypertension (HT), yet diagnostic work-up of PA remains challenging.Aim: To describe the characteristics of hypertensive patients diagnosed with PA, biochemical screening (aldosterone:renin ratio/ARR), confirmatory tests, and adrenal CT results.Methods: Clinical, hormonal and imaging evaluation.Results: 13 patients (7M/6F) with PA were 45 yrs (40&#1...

Primary hypophysitis is a rare inflammatory condition which is mostly encountered in women. It represents 0.2–0.8% of pituitary pathologies and its annual incidence is estimated at 1 case per 9 million inhabitants. We present the case of a 28-year-old male, smoker, with sudden onset decreased libido, polyuria and polydipsia. At presentation he had an epicranial lipoma with and no other suggestive clinical signs. Biochemistry revealed hypernatremia 146 nmol/L, low testoste...

Introduction: Pheochromocytomas (PHEOs) are tumors arising from medulla chromaffin cells. Their diagnosis is challenging due to a large clinical spectrum – from classical crisis to completely asymptomatic. Approximately 5.0–6.5% of adrenal incidentalomas are pheochromocytomas, and 8% of pheochromocytomas are completely asymptomatic, usually in a familial form.Aim: To compare biochemical and imagistic features of symptomatic/asymptomatic PHEOs.<...

Background: Overt parathyroid bone disease is a rare entity. We present a case of primary hyperparathyroidism (PHPT) and osteitis fibrosa cystica with involvement of multiple facial bones and neurocranium. Although the initial differential diagnosis was between acromegaly and bone malignancy, endocrine assessment demonstrated PHPT, with favorable outcome after parathyroidectomy.Case report: A 59-year-old woman referred to our clinic with painful swelling...

Introduction: Pheochromocytomas are rarely malignant, defined by the presence of cathecholamine – producing metastases. Malignant pheochromocytoma responds poorly to chemotherapy and radiotherapy. 131I-MIBG therapy can be used to prolong survival, with minor side effects.Case: A 45-years old woman known with malignant pheochromocytoma, with a long medical history, first came to our clinic in July 2012. Her diagnosis was suspected in 1999 ...

Introduction: The pituitary non-secreting microadenomas (or incidentalomas) are frequently diagnosed over the last decades thanks to imagery scan progresses and access. The gonadal dysfunction, as well as other pituitary deficiency is related to common genetic backup (+/− other pituitary dysfunctions) or may be incidental.Aim: We analyzed the endocrine profile in pituitary incidentalomas (microadenomas).Material and method: A...

Introduction: The metabolic complications in adrenal tumors, regardless secretor or not, are a common finding, thus representing a supplementary warning in these patients related to the non-endocrine therapy as anti-hypertensives, or hypolipemiants drugs, etc.Aim: We analyze the frequency of metabolic complications in primitive adrenal tumors.Materials and methods: This is a retrospective study in patients diagnosed with adrenal tu...

AbstractThyroid angiosarcoma is an aggressive and very rare type of thyroid malignancy originally diagnosed in iodine-deficient areas. The prognosis is poor and in most cases surgery proved to be inefficient. The fine needle aspiration biopsy (FNAB) and histology can rarely differentiate angiosarcoma from anaplastic carcinoma, and the final diagnosis is based on immunopositivity for vascular markers and absence of epithelial markers. We present he...

Introduction: Remission rate in microprolactinomas after treatment with dopamine agonists (DA) is variable, from about 25% in bromocriptine-treated patients to 46% in those treated with cabergoline.Patients: We retrospectively studied the remission rate in 98 patients with prolactinomas ≤1 cm evaluated in 1982–2009 in our department and treated with DA for at least 1 year.Results: Mean age of patients is 26.5±8 year...